The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
 
Inge Marie Svane
Stock and Other Ownership Interests - IO Biotech
Honoraria - BMS; IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; Sanofi/Aventis; TILT Biotherapeutics
Consulting or Advisory Role - IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; TILT Biotherapeutics
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); IO Biotech (Inst); Lytix Biopharma (Inst); TILT Biotherapeutics (Inst)
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer
 
Santosh M. Nair
No Relationships to Disclose
 
Igor Puzanov
Stock and Other Ownership Interests - Celldex; Celldex (I)
Consulting or Advisory Role - Amgen; Iovance Biotherapeutics; Merck; Nektar; Nouscom; Oncorus; Roche; Seneca Therapeutics
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Jessica Cecile Hassel
Honoraria - Almirall Hermal GmbH; Amgen; Bristol Myers Squibb Foundation; GlaxoSmithKline; MSD; Novartis; Pierre Fabre; Roche Pharma AG; Sanofi; Sun Pharma
Consulting or Advisory Role - MSD; Sanofi Aventis GmbH; Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Idera (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - 4SC
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
 
Anita Vedel Christiansen
Employment - IO Biotech
Stock and Other Ownership Interests - IO Biotech
 
Kath Lowery
Employment - IO Biotech
Stock and Other Ownership Interests - AstraZeneca
 
Kristine Pemberton
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Carrick Therapeutics; IO Biotech
 
Mohammad Al Hajj
Employment - IO Biotech
Leadership - IO Biotech
Stock and Other Ownership Interests - IO Biotech
Patents, Royalties, Other Intellectual Property - University of Michigan
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Eva Ehrnrooth
Employment - IO Biotech
Leadership - IO Biotech
Stock and Other Ownership Interests - IO Biotech
 
Alexander M. Eggermont
Stock and Other Ownership Interests - IO Biotech; RiverD; Skyline Diagnostics
Honoraria - Agenus; BIOCAD; BIOINVENT; BioNTech; CatalYm; Ellipses Pharma; GlaxoSmithKline; IO Biotech; ISA Pharmaceuticals; Merck; MSD; NEKTAR; Novartis; Pfizer; Sairopa; Sellas Life Sciences; Skyline Diagnostics
Consulting or Advisory Role - Agenus; BioCad; BIOINVENT; CatalYm; Ellipses Pharma; GlaxoSmithKline; IO BIOTECH; IO Biotech; ISA Pharmaceuticals; Merck; MSD; NEKTAR; Novartis; Pfizer; Sairopa; Sellas Life Sciences; Skyline Diagnostics
Speakers' Bureau - BIOCAD; Bristol-Myers Squibb.; Merck; MSD